Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults aged 18 years or older who are hospitalized for hypervolemic AHF, with evidence of congestion defined as either:~   \* 2 of the following signs or symptoms: peripheral edema, ascites, jugular venous pressure \> 10mmHg, orthopnea, paroxysmal nocturnal dyspnea, 5-pound weight gain, or signs of congestion on chest x-ray or lung ultrasound.~   OR~   \*If pulmonary artery catheterization is available, a pulmonary capillary wedge pressure greater than 19 mmHg plus a systemic physical exam finding of hypervolemia from the list above.~2. Randomized within 24 hours of hospitalization for AHF~3. Planned use of IV loop diuretic therapy during current hospitalization~4. Estimated glomerular filtration rate (eGFR) of at least 30 ml/min/1.73m2 by the MDRD equation~5. For diabetic patients, history of type 2 diabetes or a new hemoglobin A1c 6.5% on admission.~Exclusion Criteria:~1. Type 1 diabetes mellitus.~2. Dyspnea primarily due to non-cardiac causes.~3. Cardiogenic shock.~4. Acute coronary syndrome within 30 days prior to randomization.~5. Planned or recent percutaneous or surgical coronary intervention within 30 days prior to randomization.~6. Signs of ketoacidosis and/or hyperosmolar hyperglycemic syndrome (pH\>7.30 and glucose \>15 mmol/L and HCO3\>18 mmol/L).~7. Pregnant or nursing (lactating) women.~8. Heart failure due to drug toxicity~9. Adherence to medication less than 95%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dapagliflozine 10mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).